Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Switching antipsychotic therapies
Autore:
Masand, PS; Berry, SL;
Indirizzi:
SUNY Hlth Sci Ctr, Dept Psychiat, Psychopharmacol Consultat & Training Program, Syracuse, NY 13210 USA SUNY Hlth Sci Ctr Syracuse NY USA 13210 g Program, Syracuse, NY 13210 USA SUNY Hlth Sci Ctr, Psychiat Consultat Serv, Syracuse, NY 13210 USA SUNY Hlth Sci Ctr Syracuse NY USA 13210 ltat Serv, Syracuse, NY 13210 USA
Titolo Testata:
ANNALS OF PHARMACOTHERAPY
fascicolo: 2, volume: 34, anno: 2000,
pagine: 200 - 207
SICI:
1060-0280(200002)34:2<200:SAT>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
CHRONIC-SCHIZOPHRENIC PATIENTS; DOUBLE-BLIND; RISPERIDONE TREATMENT; COGNITIVE FUNCTIONS; OLANZAPINE TRIAL; LONG-TERM; CLOZAPINE; HALOPERIDOL; PLACEBO; MANIA;
Keywords:
antipsychotics; typical; atypical;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
57
Recensione:
Indirizzi per estratti:
Indirizzo: Masand, PS SUNY Hlth Sci Ctr, Dept Psychiat, Psychopharmacol Consultat & Training Program, 750 E Adams St, Syracuse, NY 13210 USA SUNY Hlth Sci Ctr 750 E Adams St Syracuse NY USA 13210 3210 USA
Citazione:
P.S. Masand e S.L. Berry, "Switching antipsychotic therapies", ANN PHARMAC, 34(2), 2000, pp. 200-207

Abstract

BACKGROUND: Atypical antipsychotics are superior to conventional antipsychotics in improving positive and negative psychotic symptoms. Atypical antipsychotics do not exacerbate mood symptoms, and may improve mood symptoms and cognitive functioning; additionally, they have better adverse effect profiles than conventional antipsychotics. OBJECTIVE: To review the benefits of switching patients with schizophreniaor schizoaffective disorder from a conventional to an atypical antipsychotic, or from one atypical antipsychotic to another. In spite of the higher acquisition cost of atypical antipsychotics, overall treatment costs may decrease due to lower relapse and hospitalization rates. DATA SOURCES: A MEDLINE search (January 1977-January 1999) was conducted for articles written in English about efficacy, adverse effects, compliance,and pharmacoeconomics for atypical and conventional antipsychotics. STUDY SELECTION: Large, multicenter, double-blind, controlled studies wereused for efficacy, safety, tolerability, and pharmacoeconomic data. Where appropriate, recent review articles were also used. RESULTS: Atypical antipsychotics are superior to conventional antipsychotics in the treatment of schizophrenia. Atypical and conventional antipsychotics have different adverse effect profiles, costs, and compliance rates. CONCLUSIONS: Some patients may benefit by switching from a conventional toan atypical antipsychotic, from an atypical to a conventional antipsychotic, or from one atypical antipsychotic to another. Methods of switching antipsychotic therapies include tapering and cross-over strategies.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/20 alle ore 21:57:58